The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Who can participate
Inclusion Criteria:
* Age 18 to ≤ 85 years
* Lp(a) ≥ 200 nmol/L during screening
* History of ASCVD as evidenced by history of either:
* Myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or
* Coronary revascularization with percutaneous coronary intervention AND at least 1 additional risk factor.
Exclusion Criteria:
* Severe renal dysfunction
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or total bilirubin (TBL) \> 2 x ULN during screening
* History of hemorrhagic stroke
* History of major bleeding disorder
* Planned cardiac surgery or arterial revascularization
* Severe heart failure
* Current, recent, or planned lipoprotein apheresis
* Previously received ribonucleic acid therapy specifically targeting Lp(a)
Locations
31
Argentina (1)
Instituto de Investigaciones Clinicas Bahia Blanca
Bahía Blanca , Buenos Aires
Australia (1)
Canberra Hospital
Garran , Australian Capital Territory
Belgium (1)
Algemeen Stedelijk Ziekenhuis Aalst
Aalst
Brazil (1)
Hospital Universitario Walter Cantidio
Fortaleza , Ceará
Bulgaria (1)
Multiprofile Hospital for Active Treatment Puls AD
Blagoevgrad
Canada (1)
ARC Biosystems Incorporated
Vancouver , British Columbia
China (1)
Peking University Third Hospital
Beijing , Beijing Municipality
Czech Republic (1)
Jessenia as, Nemocnice Beroun
Beroun
Denmark (1)
Aalborg Universitetshospital
Aalborg
Estonia (1)
Innomedica
Tallinn
Finland (1)
Helsinki University Central Hospital
Helsinki
France (1)
Centre Hospitalier Regional Universitaire de Besancon, Hopital Jean Minjoz
БГ